Tonix Pharmaceuticals Launches TONMYA Commercially After First New Fibromyalgia Approval in 15 Years

TONMYA's first full commercial quarter reveals the operational realities of launching a CNS drug into a market that has seen no new approved therapy in over 15 years. Tonix Pharmaceuticals reported that 2,145 unique healthcare providers prescribed the cyclobenzaprine HCl sublingual tablet in Q1 2026, with 3,588 patients initiating treatment and approximately 5,400 prescriptions filled, a figure that includes bridge prescriptions processed through specialty pharmacy while coverage determinations remain pending.

The bridge prescription dynamic is a meaningful variable for commercial operations teams. Those fills do not immediately generate net product revenue, which means the gap between prescription volume and recognized revenue will remain a tracking point for finance and market access functions through the coverage determination cycle. A group purchasing organization (GPO) agreement signed in May now extends formulary access to approximately 35 million U.S. commercial lives, representing the first managed care partnership since the November 2025 launch.

TONMYA received FDA approval in August 2025 under a pathway supported by two double-blind, randomized, placebo-controlled Phase 3 studies enrolling nearly 1,000 patients, with results demonstrating statistically significant and durable reductions in daily pain scores versus placebo. The approval adds a non-opioid, bedtime-administered option to a therapeutic area where prescribing options have been limited to agents approved before 2010. Approximately 100 field sales representatives are currently deployed.

On the pipeline side, TNX-4800, an investigational long-acting human monoclonal antibody targeting OspA on Borrelia burgdorferi, is advancing toward a scheduled Type C meeting with FDA in early Q3 2026 to align on the design of an adaptive Phase 2 field study for Lyme disease prevention. Positive Phase 1 data have been reported; Phase 2 initiation in the U.S. is targeted for the first half of 2027, pending FDA agreement. For regulatory affairs leads tracking biologics development strategy, the Type C meeting structure here reflects a pre-Phase 2 alignment approach consistent with ICH Q8 design-space thinking applied to clinical endpoints in infectious disease.

Tonix also expects to initiate a Phase 2 study of TONMYA for Major Depressive Disorder mid-2026, extending the cyclobenzaprine program into a second CNS indication. Cash and cash equivalents stood at approximately $185.5 million as of March 31, 2026.

The GPO agreement's coverage reach and the outcome of the Q3 FDA Type C meeting for TNX-4800 will serve as the two near-term indicators of whether Tonix's commercial and regulatory execution can sustain the trajectory established in the launch quarter.

Source: Tonix Pharmaceuticals Holding Corp. via GlobeNewswire, May 11, 2026.